Evidence map›Paper›PMID 38433576›Full record

ArticleActa biochimica et biophysica Sinica2024

Abrogation of KLF5 sensitizes

Zheng Zhang, Yuxin Liu, Yaolin Xu, Zijin Xu, Jinbin Jia, Yun Jin, Wenquan Wang, Liang Liu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Zheng ZhangDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yuxin LiuInstitute of Liver Diseases, Shanxi Medical University, Taiyuan 030001, China.
Yaolin XuDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Zijin XuDepartment of General Surgery, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, 201700, China.
Jinbin JiaInstitute of Liver Diseases, Shanxi Medical University, Taiyuan 030001, China.
Yun JinDepartment of Hepatobiliary and Pancreatic Surgery, the First People's Hospital of Yunnan Province, the Affiliated Hospital of Kunming University of Science and Technology, Kunming 650500, China.
Wenquan WangDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Liang LiuDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Fudan University · CNSun Yat-sen University · CNThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poly ADP-ribose polymerase (PARP) inhibitor monotherapies are selectively effective in patients with pancreatic, breast, prostate, and ovarian cancers with

Indexed as

Antineoplastic AgentsKruppel-Like Transcription FactorsPancreatic NeoplasmsBRCA1 ProteinCell Line, TumorDNA RepairHumansOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsBRCA1 ProteinBRCA1 protein, humanKLF5 protein, humanKruppel-Like Transcription FactorsPoly(ADP-ribose) Polymerase InhibitorsBRCA1BRCAnessKLF5pancreatic cancerwild-type

Identifiers

PMID38433576
PMCPMC11090855
OpenAlexW4390276377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.